Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 19/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 19/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 19/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 19/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 19/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23003576 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL20590001 | 0.87 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL31275848 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL18705654 | 0.81 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL19948600 | 0.79 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1404444 | 0.79 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL5965871 | 0.77 | CHRNB2 (0.59) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL18498189 | 0.77 | NAMPT (0.34) | CHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL7006653 | 0.76 | CHRNB2 (0.57) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL30259993 | 0.76 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| EP-4329888-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232332-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-3980412-A2 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-2773199-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9139585-B2 | Inhibitors of the Renal Outer Medullary Potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140309213-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-10-16 | — | — | US | disclosed |
| EP-2773199-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013066714-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | CHRNB2 4113/4885CHRNA3 4526/4885CHRNA4 4620/4885 |
| US-20140309213-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ2, KCNJ11, KCNJ1 | CHRNB2 1398/4885CHRNA3 1691/4885CHRNA4 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.